MCID: TBR024
MIFTS: 65

Tuberous Sclerosis-1 malady

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Eye diseases, Nephrological diseases, Skin diseases, Fetal diseases

Aliases & Classifications for Tuberous Sclerosis-1

About this section
Sources:
11Disease Ontology, 12diseasecard, 13DISEASES, 23GeneReviews, 24GeneTests, 25Genetics Home Reference, 26GTR, 29ICD10, 30ICD10 via Orphanet, 31ICD9CM, 36MedGen, 37MedlinePlus, 38MeSH, 39MESH via Orphanet, 44NCIt, 47NIH Rare Diseases, 48NINDS, 49Novoseek, 51OMIM, 53Orphanet, 61SNOMED-CT, 63The Human Phenotype Ontology, 67UMLS, 68UMLS via Orphanet, 69UniProtKB/Swiss-Prot
See all MalaCards sources

Aliases & Descriptions for Tuberous Sclerosis-1:

Name: Tuberous Sclerosis-1 51 12
Tuberous Sclerosis 11 47 48 53 69 49 37 38 13 67
Tuberous Sclerosis Complex 23 47 24 25 53 69
Tuberous Sclerosis 1 47 24 69 67
Bourneville Syndrome 47 53 69
Bourneville Disease 23 24 25
Epiloia 11 24 25
Tuberous Sclerosis Syndrome 11 26
Tuberous Sclerosis, Type 1 47 26
Bourneville's Disease 11 24
 
Tuberose Sclerosis 11 25
Cerebral Sclerosis 11 25
Tsc1 24 69
Bourneville Pringle Syndrome 24
Bourneville Phakomatosis 25
Bourneville's Syndrome 47
Sclerosis Tuberosa 25
Phakomatosis Ts 24
Ts 69

Characteristics:

Orphanet epidemiological data:

53
tuberous sclerosis:
Inheritance: Autosomal dominant; Prevalence: 1-9/1000000 (United States),1-5/10000 (Europe),1-9/100000 (Ireland),1-9/100000 (United Kingdom),1-5/10000 (United Kingdom),1-9/100000 (United States),1-9/100000 (Taiwan, Province of China); Age of onset: All ages; Age of death: any age

HPO:

63
tuberous sclerosis-1:
Inheritance: autosomal dominant inheritance
Onset and clinical course: phenotypic variability

GeneReviews:

23
Penetrance: after detailed evaluation of each individual known to have a tsc1 or tsc2 pathogenic variant, the penetrance of tsc is now thought to be 100%. rare instances of apparent non-penetrance have been reported; however, molecular studies revealed the presence of two different pathogenic variants in the family and the existence of germline mosaicism in others [connor et al 1986, webb & osborne 1991, rose et al 1999]...


Classifications:



External Ids:

OMIM51 191100
Disease Ontology11 DOID:13515
ICD1029 Q85.1
ICD9CM31 759.5
MeSH38 D014402
NCIt44 C3424
Orphanet53 ORPHA805
ICD10 via Orphanet30 Q85.1
MESH via Orphanet39 D014402
UMLS via Orphanet68 C0041341

Summaries for Tuberous Sclerosis-1

About this section
OMIM:51 Tuberous sclerosis complex (TSC) is an autosomal dominant multisystem disorder characterized by hamartomas in multiple... (191100) more...

MalaCards based summary: Tuberous Sclerosis-1, also known as tuberous sclerosis, is related to lymphangioleiomyomatosis and polycystic kidney disease, infantile severe, with tuberous sclerosis, and has symptoms including prominent occiput, eeg abnormality and neoplasm of the nervous system. An important gene associated with Tuberous Sclerosis-1 is TSC1 (Tuberous Sclerosis 1), and among its related pathways are LKB1 signaling events and Constitutive Signaling by AKT1 E17K in Cancer. Affiliated tissues include skin, kidney and brain, and related mouse phenotypes are liver/biliary system and respiratory system.

Genetics Home Reference:25 Tuberous sclerosis complex is a genetic disorder characterized by the growth of numerous noncancerous (benign) tumors in many parts of the body. These tumors can occur in the skin, brain, kidneys, and other organs, in some cases leading to significant health problems. Tuberous sclerosis complex also causes developmental problems, and the signs and symptoms of the condition vary from person to person.

MedlinePlus:37 Tuberous sclerosis is a rare genetic disease that causes benign tumors to grow in the brain and other organs. symptoms vary, depending on where the tumors grow. they could include skin problems, such as light patches and thickened skin seizures behavior problems intellectual disabilities kidney problems some people have signs of tuberous sclerosis at birth. in others it can take time for the symptoms to develop. the disease can be mild, or it can cause severe disabilities. in rare cases, tumors in vital organs or other symptoms can be life-threatening. tuberous sclerosis has no cure, but treatments can help symptoms. options include medicines, educational and occupational therapy, surgery, or surgery to treat specific complications. nih: national institute of neurological disorders and stroke

NINDS:48 Tuberous sclerosis (TSC) is a rare genetic disease that causes benign tumors to grow in the brain and on other vital organs such as the kidneys, heart, eyes, lungs, and skin. It usually affects the central nervous system. In addition to the benign tumors that frequently occur in TSC, other common symptoms include seizures,impaired intellectual development, behavior problems, and skin abnormalities. TSC may be present at birth, but signs of the disorder can be subtle and full symptoms may take some time to develop. Three types of brain tumors are associated with TSC: cortical tubers, which generally form on the surface of the brain; subependymal nodules, which form in the walls of the ventricles (the fluid-filled cavities of the brain); and giant-cell astrocytomas, a type of tumor that can block the flow of fluids within the brain.

UniProtKB/Swiss-Prot:69 Tuberous sclerosis 1: An autosomal dominant multi-system disorder that affects especially the brain, kidneys, heart, and skin. It is characterized by hamartomas (benign overgrowths predominantly of a cell or tissue type that occurs normally in the organ) and hamartias (developmental abnormalities of tissue combination). Clinical manifestations include epilepsy, learning difficulties, behavioral problems, and skin lesions. Seizures can be intractable and premature death can occur from a variety of disease-associated causes.

GeneReviews for NBK1220

Related Diseases for Tuberous Sclerosis-1

About this section

Diseases related to Tuberous Sclerosis-1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 79)
idRelated DiseaseScoreTop Affiliating Genes
1lymphangioleiomyomatosis33.1CCL26, COL5A1, TSC1, TSC2
2polycystic kidney disease, infantile severe, with tuberous sclerosis12.2
3sudanophilic cerebral sclerosis12.0
4cerebral sclerosis similar to pelizaeus-merzbacher disease11.8
5gilles de la tourette syndrome11.7
6turner syndrome11.7
7adrenoleukodystrophy11.2
8metachromatic leukodystrophy11.1
9tsc2 angiomyolipomas, renal, modifier of11.1
10mitochondrial dna depletion syndrome 4a11.0
11tumefactive multiple sclerosis11.0
12timothy syndrome10.9
13pelizaeus-merzbacher disease10.8
14balo concentric sclerosis10.8
15myelinoclastic diffuse sclerosis10.8
16chromosome 16q duplication10.7PKD1, TSC2
17spinocerebellar ataxia, autosomal recessive 210.7MTOR, TSC1
18kohlschutter-tonz syndrome10.7PKD1, TSC2
19buschke-ollendorff syndrome10.7TSC1, TSC2
20ataxia10.6CCL26, TSC2
21basal ganglia calcification10.6NF1, PKD1
22glomeruloid hemangioma10.6GFAP, NF1
23congenital fibrosarcoma10.6MTOR, TSC1, TSC2
24tenosynovitis of foot and ankle10.5MTOR, TSC1, TSC2
25epithelioid type angiomyolipoma10.5MTOR, TSC1, TSC2
26malignant struma ovarii10.5CCL26, TSC1, TSC2
27myopathy with deficiency of iron-sulfur cluster assembly enzyme10.5DCX, TSC1, TSC2
28grubben de cock borghgraef syndrome10.5GFAP, SYP
29papillary glioneuronal tumor10.5GFAP, SYP
30renal clear cell carcinoma10.5TSC1, TSC2
31bladder flat intraepithelial lesion10.5GFAP, SYP
32retinal melanoma10.5NF1, SYP
33lice infestation10.5GFAP, SYP
34chiari malformation type 410.4GFAP, SYP
35cauda equina neoplasm10.4GFAP, SYP
36brain glioma10.4GFAP, SYP
37pseudoglandular variant testicular seminoma10.4GFAP, NF1
38vulvar benign neoplasm10.4GFAP, SYP
39rectum adenoma10.4EIF4EBP1, MTOR
40hypersensitivity reaction type ii disease10.4GFAP, SYP
41brainstem intraparenchymal clear cell meningioma10.4GFAP, SYP
42jewett-marshall bladder cancer10.3GFAP, SYP
43herpes simplex encephalitic 610.3PTEN, TSC1, TSC2
44mucopolysaccharidoses10.3MTOR, PTEN, TSC1
45peritoneal benign neoplasm10.3GFAP, NF1, SYP
46adenomyoma of uterine corpus10.3GFAP, NF1, SYP
47y-linked disease10.3NF1, PKD1, PKHD1
48compartment syndrome10.3GFAP, NF1, PTEN
49lumbar plexus neoplasm10.3GFAP, SYP
50tumor predisposition syndrome10.3NF1, PTEN, TSC2

Graphical network of the top 20 diseases related to Tuberous Sclerosis-1:



Diseases related to tuberous sclerosis-1

Symptoms for Tuberous Sclerosis-1

About this section

Symptoms by clinical synopsis from OMIM:

191100

Clinical features from OMIM:

191100

Human phenotypes related to Tuberous Sclerosis-1:

 63 53 (show all 77)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 prominent occiput63 53 hallmark (90%) Very frequent (99-80%) HP:0000269
2 eeg abnormality63 53 hallmark (90%) Very frequent (99-80%) HP:0002353
3 neoplasm of the nervous system63 hallmark (90%) HP:0004375
4 adenoma sebaceum63 hallmark (90%) HP:0009720
5 optic atrophy63 53 typical (50%) Frequent (79-30%) HP:0000648
6 behavioral abnormality63 53 typical (50%) Frequent (79-30%) HP:0000708
7 cafe-au-lait spot63 typical (50%) HP:0000957
8 hypermelanotic macule63 typical (50%) HP:0001034
9 hypopigmented skin patches63 53 typical (50%) Frequent (79-30%) HP:0001053
10 seizures63 53 typical (50%) Frequent (79-30%) HP:0001250
11 retinal hamartoma63 53 typical (50%) Frequent (79-30%) HP:0009594
12 cognitive impairment63 typical (50%) HP:0100543
13 ungual fibroma63 53 typical (50%) Very frequent (99-80%) HP:0100804
14 intellectual disability63 53 30% Frequent (79-30%) HP:0001249
15 renal insufficiency63 53 occasional (7.5%) Occasional (29-5%) HP:0000083
16 polycystic kidney dysplasia63 occasional (7.5%) HP:0000113
17 gingivitis63 53 occasional (7.5%) Occasional (29-5%) HP:0000230
18 iris coloboma63 53 occasional (7.5%) Occasional (29-5%) HP:0000612
19 abnormality of dental enamel63 occasional (7.5%) HP:0000682
20 hypothyroidism63 53 occasional (7.5%) Occasional (29-5%) HP:0000821
21 precocious puberty63 53 occasional (7.5%) Occasional (29-5%) HP:0000826
22 abnormality of the liver63 53 occasional (7.5%) Occasional (29-5%) HP:0001392
23 congestive heart failure63 53 occasional (7.5%) Occasional (29-5%) HP:0001635
24 abnormality of the pancreas63 53 occasional (7.5%) Occasional (29-5%) HP:0001732
25 respiratory insufficiency63 53 occasional (7.5%) Occasional (29-5%) HP:0002093
26 emphysema63 53 occasional (7.5%) Occasional (29-5%) HP:0002097
27 abnormality of the pleura63 53 occasional (7.5%) Occasional (29-5%) HP:0002103
28 cerebral calcification63 53 occasional (7.5%) Occasional (29-5%) HP:0002514
29 increased intracranial pressure63 53 occasional (7.5%) Occasional (29-5%) HP:0002516
30 aneurysm63 53 occasional (7.5%) Occasional (29-5%) HP:0002617
31 aplasia/hypoplasia of the corpus callosum63 53 occasional (7.5%) Occasional (29-5%) HP:0007370
32 renal neoplasm63 occasional (7.5%) HP:0009726
33 arrhythmia63 53 occasional (7.5%) Occasional (29-5%) HP:0011675
34 neoplasm of the heart63 occasional (7.5%) HP:0100544
35 macrodactyly of finger63 occasional (7.5%) HP:0100746
36 visceral angiomatosis63 occasional (7.5%) HP:0100761
37 lymphangioma63 occasional (7.5%) HP:0100764
38 renal cyst63 HP:0000107
39 gingival fibromatosis63 53 Occasional (29-5%) HP:0000169
40 autism63 HP:0000717
41 specific learning disability63 HP:0001328
42 subcutaneous nodule63 HP:0001482
43 wolff-parkinson-white syndrome63 HP:0001716
44 abnormality of the respiratory system63 53 Occasional (29-5%) HP:0002086
45 ependymoma63 HP:0002888
46 renal cell carcinoma63 HP:0005584
47 renal angiomyolipoma63 53 Occasional (29-5%) HP:0006772
48 attention deficit hyperactivity disorder63 HP:0007018
49 projection of scalp hair onto lateral cheek63 HP:0009554
50 astrocytoma63 HP:0009592
51 subependymal nodules63 53 Very frequent (99-80%) HP:0009716
52 cortical tubers63 HP:0009717
53 hypomelanotic macule63 HP:0009719
54 shagreen patch63 53 Frequent (79-30%) HP:0009721
55 dental enamel pits63 53 Occasional (29-5%) HP:0009722
56 subungual fibromas63 HP:0009724
57 achromatic retinal patches63 53 Frequent (79-30%) HP:0009727
58 cardiac rhabdomyoma63 53 Occasional (29-5%) HP:0009729
59 optic glioma63 HP:0009734
60 chordoma63 HP:0010762
61 infantile spasms63 HP:0012469
62 premature chromatid separation63 HP:0200024
63 nevus flammeus53 Frequent (79-30%)
64 global developmental delay53 Frequent (79-30%)
65 pneumothorax53 Occasional (29-5%)
66 cortical dysplasia53 Frequent (79-30%)
67 neoplasm of the pancreas53 Occasional (29-5%)
68 macrodactyly53 Occasional (29-5%)
69 multiple renal cysts53 Occasional (29-5%)
70 confetti-like hypopigmented macules53 Frequent (79-30%)
71 multiple cafe-au-lait spots53 Frequent (79-30%)
72 subependymal giant-cell astrocytoma53 Very frequent (99-80%)
73 chylothorax53 Occasional (29-5%)
74 skin tags53 Very frequent (99-80%)
75 angiofibromas53 Very frequent (99-80%)
76 pulmonary lymphangiomyomatosis53 Occasional (29-5%)
77 papule53 Very frequent (99-80%)

UMLS symptoms related to Tuberous Sclerosis-1:


back pain, headache, pain, sciatica, seizures, syncope, tremor, chronic pain, umbilical discharge, osler's node, abnormal granulation tissue, vertigo/dizziness, skin symptom, sleeplessness

Drugs & Therapeutics for Tuberous Sclerosis-1

About this section

Drugs for Tuberous Sclerosis-1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 75)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Sirolimusapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1189653123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
2
EverolimusapprovedPhase 4, Phase 3, Phase 2, Phase 11896159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
everolimus
3
Miconazoleapproved, investigational, vet_approvedPhase 4, Phase 3, Phase 2, Phase 1362422916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
4
Doxycyclineapproved, investigational, vet_approvedPhase 4237564-25-054671203
Synonyms:
(2E,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(2Z)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(2Z,4S,4aR,5S,5aR,6R)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(2Z,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
10597-92-9
17086-28-1 (mono-hydrate)
2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)
24390-14-5
41411-66-9 (6-epimer, mono-hydrochloride)
5-Hydroxy-alpha-6-deoxytetracycline
5-hydroxy-α-6-deoxytetracycline
564-25-0
6-Deoxyoxytetracycline
6-Deoxytetracycline
6-alpha-Deoxy-5-oxytetracycline
6-alpha-deoxy-5-oxytetracycline
69935-17-7 (mono-hydrochloride, di-hydrate)
6alpha-Deoxy-5-oxytetracycline
6alpha-deoxy-5-oxytetracycline
6α-deoxy-5-oxytetracycline
7164-70-7
7264-10-0
94088-85-4 (calcium salt (1:2))
AB08 (*Fosfatex)
AC1NQXW7
AC1NS4CW
AC1NUYS8
AC1O8PYM
Alti-Doxycycline
Anhydrous doxycycline
Apo-Doxy
Atridox
Azudoxat
BCBcMAP01_000024
BIDD:GT0146
BMY-28689
BPBio1_000951
BSPBio_000863
BSPBio_001936
BU-3839T
C06973
CHEBI:50845
CHEMBL1433
CID5281011
CID5353597
CID5463943
CID6713981
CPD001550033
D07876
DB00254
DMSC (*Fosfatex)
DOXCYCLINE ANHYDROUS
DOXY
DOXYCYCLINE CALCIUM
DOXYCYCLINE MONOHYDRATE
Deoxymykoin
DivK1c_000345
Dossiciclina
Dossiciclina [DCIT]
Doxcycline anhydrous
Doxiciclina
Doxiciclina [INN-Spanish]
Doxiciclina [Italian]
Doxitard
Doxivetin
Doxy-Caps
Doxy-Puren
Doxy-Tabs
Doxycen
Doxychel
Doxychel (TN)
Doxycin
Doxycyclin
Doxycycline (200mg/day) or Placebo
 
Doxycycline (INN)
Doxycycline (TN)
Doxycycline (anhydrous)
Doxycycline (internal use)
Doxycycline Hyclate
Doxycycline Monohydrate
Doxycycline anhydrous
Doxycycline hyclate
Doxycycline-Chinoin
Doxycyclinum
Doxycyclinum [INN-Latin]
Doxysol
Doxytec
Doxytetracycline
EINECS 209-271-1
GS-3065 (*monohydrate)
HMS2090E06
HSDB 3071
Hydramycin
IDI1_000345
Investin
Jenacyclin
KBio1_000345
KBio2_001287
KBio2_003855
KBio2_006423
KBio3_001156
KBioGR_001133
KBioSS_001287
LS-187766
LS-93868
Liviatin
Lopac0_000405
MolPort-002-507-423
Monodox
Monodox (*monohydrate)
NCGC00161602-01
NCGC00161602-03
NCGC00161602-04
NCGC00167961-01
NCGC00179395-01
NINDS_000345
NSC633557
Novo-Doxylin
Nu-Doxycycline
Oracea
Prestwick0_000852
Prestwick1_000852
Prestwick2_000852
Prestwick3_000852
Ronaxan
SAM002589932
SMP1_000107
SPBio_000246
SPBio_002784
STOCK1N-34341
Spanor
Spectrum2_000143
Spectrum3_000408
Spectrum4_000527
Spectrum5_000947
Spectrum_000807
Supracyclin
UNII-334895S862
UPCMLD-DP021
UPCMLD-DP021:001
Vibra-tabs
Vibramycin
Vibramycin (*monohydrate)
Vibramycin Novum
Vibramycine
Vibravenos
Vivox (*Hyclate)
alpha-6-Deoxy-5-hydroxytetracycline
alpha-6-Deoxyoxytetracycline
alpha-Doxycycline
doxycycline
5
VigabatrinapprovedPhase 4, Phase 22168506-86-5, 60643-86-95665
Synonyms:
( inverted question mark)-gamma-Vinyl GABA
(?)-gamma-Vinyl GABA
(R,S)-4-Amino-5-hexenoic acid
.gamma.-Vinyl-.gamma.-aminobutyric acid
.gamma.-Vinyl-GABA
4-Amino-5-hexenoic acid
4-Aminohexenoic acid
4-aminohex-5-enoic acid
60643-86-9
74046-07-4
AB00053309
AC1L1KUZ
Acid, gamma-Vinyl-gamma-Aminobutyric
Aventis Brand of Vigabatrin
BPBio1_000465
BPBio1_000925
BSPBio_000421
BSPBio_003469
Biomol-NT_000247
C07500
C6H11NO2
CHEBI:241484
CHEMBL89598
CID5665
CPP-109
D00535
D020888
DB01080
DivK1c_006760
EU-0101277
GVG
Gamma vinyl GABA
HMS1569F03
HMS2094M21
Hexenoic acid, 4-amino
Hoechst Brand of Vigabatrin
KBio1_001704
KBio2_000848
KBio2_003416
KBio2_005984
KBio3_002973
KBioSS_000848
LS-75569
Lopac0_001277
M071754
MDL 71,754
MDL 71754
 
MDL-71754
MolPort-003-666-796
NCGC00016087-03
NCGC00016087-08
NCGC00024802-02
NCGC00024802-03
NCGC00024802-04
NCGC00024802-05
NCGC00024802-06
Prestwick0_000501
Prestwick1_000501
Prestwick2_000501
Prestwick3_000501
Prestwick_837
RMI 71754
RMI-71754
RMI-71890
SPBio_002342
SPECTRUM1502036
Sabril
Sabril (TN)
Sabrilex
SpecPlus_000664
Spectrum3_001825
Spectrum_000368
V 8261
V8261_SIGMA
Vigabatrin
Vigabatrin (JAN/USAN/INN)
Vigabatrin Aventis Brand
Vigabatrin Hoechst Brand
Vigabatrin Yamanouchi Brand
Vigabatrin [USAN:BAN:INN]
Vigabatrin [USAN:INN:BAN]
Vigabatrina
Vigabatrina [Spanish]
Vigabatrine
Vigabatrine [French]
Vigabatrinum
Vigabatrinum [Latin]
Vinyl gamma-aminobutyric acid
Yamanouchi Brand of Vigabatrin
gamma Vinyl GABA
gamma Vinyl gamma Aminobutyric Acid
gamma-Vinyl GABA
gamma-Vinyl-GABA
gamma-Vinyl-gamma-Aminobutyric Acid
gamma-Vinyl-gamma-aminobutyric acid
vigabatrin
6Anti-Bacterial AgentsPhase 4, Phase 3, Phase 2, Phase 110884
7Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 121402
8Antibiotics, AntitubercularPhase 4, Phase 3, Phase 2, Phase 16972
9Antifungal AgentsPhase 4, Phase 3, Phase 2, Phase 13615
10Immunosuppressive AgentsPhase 4, Phase 3, Phase 2, Phase 112770
11AntimalarialsPhase 41216
12Neurotransmitter AgentsPhase 4, Phase 217734
13Antiparasitic AgentsPhase 42127
14Antiprotozoal AgentsPhase 41986
15AnticonvulsantsPhase 4, Phase 22620
16GABA AgentsPhase 4, Phase 21622
17
Methylprednisoloneapproved, vet_approvedPhase 3115383-43-26741
Synonyms:
(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
.DELTA.1-6.alpha.-Methylhydrocortisone
1-Dehydro-6alpha-methylhydrocortisone
1-dehydro-6alpha-Methylhydrocortisone
1-dehydro-6α-methylhydrocortisone
11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione
11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
121673-01-6
4-08-00-03498 (Beilstein Handbook Reference)
46436_FLUKA
46436_RIEDEL
570-35-4
6 Methylprednisolone
6-Methylprednisolone
6-alpha-Methylprednisolone
6.alpha.-Methylprednisolone
6923-42-8
6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
83-43-2
AC1L1N7A
Artisone-Wyeth
Artisone-wyeth
BPBio1_000174
BRD-K35240538-001-03-1
BRN 2340300
BSPBio_000158
Besonia
Bio-0658
CHEBI:6888
CHEMBL650
CID6741
CPD000058330
D00407
D008775
DB00959
Depo-Medrol (acetate)
Dopomedrol
EINECS 201-476-4
Esametone
Firmacort
HMS1568H20
HMS2090B13
HSDB 3127
LMST02030178
LS-118498
Lemod
M0639_SIGMA
M1665
MEPRDL
MLS000028541
MLS001148159
MLS002207191
Medesone
Medixon
Medlone 21
 
Medrate
Medrol
Medrol (TN)
Medrol Adt Pak
Medrol Dosepak
Medrol adt pak
Medrol dosepak
Medrol, Solu-Medrol, Medrone, Methylprednisolone
Medrone
Mesopren
Metastab
Methyleneprednisolone
Methylprednisolon
Methylprednisolone
Methylprednisolone (JP15/USP/INN)
Methylprednisolone [USAN:INN:BAN:JAN]
Methylprednisolone, 6-alpha
Methylprednisolonum
Methylprednisolonum [INN-Latin]
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [DCIT]
Metilprednisolone [Dcit]
Metipred
Metrisone
Metrocort
Metysolon
Moderin
MolPort-002-528-554
NCGC00022735-03
NCI60_001657
NSC-19987
NSC19987
Nirypan
Noretona
Predni N Tablinen
Prednol- L
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI)
Prestwick0_000279
Prestwick1_000279
Prestwick2_000279
Prestwick3_000279
Prestwick_622
Promacortine
Reactenol
S1733_Selleck
SAM002589984
SMR000058330
SPBio_002377
Sieropresol
Solomet
Summicort
Suprametil
U 7532
UNII-X4W7ZR7023
Urbason
Urbasone
Wyacort
ZINC03875560
delta(1)-6alpha-Methylhydrocortisone
delta(sup 1)-6-alpha-Methylhydrocortisone
methylprednisolone
methylprenisolone
18
Prednisoloneapproved, vet_approvedPhase 3115350-24-85755
Synonyms:
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
.DELTA.1-Cortisol
.DELTA.1-Dehydrocortisol
.DELTA.1-Dehydrohydrocortisone
.DELTA.1-Hydrocortisone
.delta.-Cortef
.delta.-Stab
1,2-Dehydrohydrocortisone
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1-Dehydrocortisol
1-Dehydrohydrocortisone
3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene
46656_FLUKA
46656_RIEDEL
50-24-8
58201-11-9
8056-11-9
AC-1773
AC1L1L2E
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
BPBio1_000164
BRD-K98039984-001-03-0
BRN 1354103
BSPBio_000148
Bio-0666
Bubbli-Pred
C07369
CCRIS 980
CHEBI:8378
CHEMBL131
CID5755
CO-Hydeltra
CPD000718761
Co-Hydeltra
Codelcortone
Cordrol
Cortalone
Cotogesic
Cotolone
D00472
D011239
DB00860
Decaprednil
Decortin H
Delcortol
Delta F
Delta(1)-dehydrohydrocortisone
Delta-Cortef
Delta-Cortef (TN)
Delta-Ef-Cortelan
Delta-Stab
Delta-stab
Deltacortenol
Deltacortril
Deltacortril Enteric
Deltahydrocortisone
Deltasolone
Deltisilone
Depo-Medrol
Derpo PD
Derpo Pd
Dexa-Cortidelt Hostacortin H
Dexa-Cortidelt hostacortin H
Di Adreson F
Di-Adreson F
Di-Adreson-F
Di-adreson F
DiAdresonF
Dicortol
Donisolone
Dydeltrone
EINECS 200-021-7
Eazolin D
Econopred
Econopred Plus
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
Fernisolone-P
Flamasone
HMS1568H10
HMS2090J05
HSDB 3385
Hostacortin H
Hydeltra
Hydeltra-Tba
Hydeltrasol
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
I-Pred
Inflamase Forte
Inflamase Mild
K 1557
Key-Pred
Klismacort
LMST02030179
LS-7669
Lentosone
Lite Pred
M-Predrol
 
MLS001304083
MLS002154250
MLS002207037
Medrol
Medrol Acetate
Metacortandralone
Methylprednisolone Acetate
Meti-Derm
Meticortelone
Metreton
MolPort-002-507-147
NCGC00179649-01
NSC 9120
NSC9120
NSC9900
Neo-Delta-Cortef
Nisolone
Nor-Pred T.B.A.
Ocu-Pred
Ocu-Pred Forte
Ophtho-Tate
Orapred
P0152_SIGMA
P0637
P6004_SIGMA
PRDL
PRED-G
Panafcortelone
Paracortol
Paracotol
Pediapred
Poly-Pred
Precortalon
Precortancyl
Precortilon
Precortisyl
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
Predisolone Sodium Phosphate
Predne-Dome
Prednelan
Predni-Dome
Prednicen
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
Prednisolone (JP15/USP/INN)
Prednisolone (anhydrous)
Prednisolone Acetate
Prednisolone Sodium Phosphate
Prednisolone Tebutate
Prednisolone [INN:BAN:JAN]
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
Prelone
Prenolone
Prestwick0_000274
Prestwick1_000274
Prestwick2_000274
Prestwick3_000274
Prestwick_404
Rolisone
S1737_Selleck
SAM002264639
SMR000718761
SPBio_002367
Scherisolon
Solone
Steran
Sterane
Sterolone
Supercortisol
UNII-9PHQ9Y1OLM
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-Hydrogen
Ultracortene-hydrogen
ZINC03833821
component of Ataraxoid
component of K-Predne-Dome
delta(1)-Cortisol
delta(1)-Dehydrocortisol
delta(1)-Dehydrohydrocortisone
delta(1)-Hydrocortisone
delta(sup 1)-Cortisol
delta(sup 1)-Dehydrocortisol
delta(sup 1)-Dehydrohydrocortisone
delta(sup 1)-Hydrocortisone
delta-dehydrocortisol
delta-dehydrohydrocortisone
delta-hydrocortisone
prednisolone
19
EthanolapprovedPhase 3204364-17-5702
Synonyms:
(C6-C9)Alkyl alcohol
02483_FLUKA
02851_FLUKA
02853_FLUKA
02854_FLUKA
02855_FLUKA
02856_FLUKA
02856_SIAL
02857_FLUKA
02857_SIAL
02858_FLUKA
02858_SIAL
02860_FLUKA
02865_FLUKA
02865_SIAL
02870_FLUKA
02870_SIAL
02875_FLUKA
02877_FLUKA
02878_FLUKA
02882_FLUKA
02882_SIAL
02883_FLUKA
02884_FLUKA
02890_FLUKA
02890_SIAL
02891_FLUKA
02891_SIAL
1-Hydroxyethane
100C.NPA
121182-78-3
187380_ALDRICH
187380_SIAL
24102_RIEDEL
24102_SIAL
24103_RIEDEL
24103_SIAL
24105_RIEDEL
24105_SIAL
24106_RIEDEL
24106_SIAL
24194_RIEDEL
24194_SIAL
245119_ALDRICH
245119_SIAL
270741_ALDRICH
270741_SIAL
277649_ALDRICH
277649_SIAL
2858_SIGMA
29221_FLUKA
32205_RIEDEL
32205_SIAL
32221_RIEDEL
32221_SIAL
32294_RIEDEL
32294_SIAL
34870_SIAL
34963_RIEDEL
39278_FLUKA
40210_ALDRICH
40210_RIEDEL
41322_FLUKA
458600_ALDRICH
458600_SIAL
459828_ALDRICH
459828_SIAL
459836_ALDRICH
459836_SIAL
459844_SIAL
48075_SUPELCO
493511_SIAL
493538_ALDRICH
493538_SIAL
493546_ALDRICH
493546_SIAL
64-17-5
676829_SIAL
68475-56-9
71076-86-3
71329-38-9
8000-16-6
8024-45-1
AC1L19TW
AC1Q31MM
AHD 2000
AI3-01706
ALCOHOL 5% IN D5-W
Absolute Alcohol
Absolute Ethanol
Absolute alcohol
Absolute ethanol
Absolute ethyl alcohol
Aethanol
Aethanol [German]
Aethylalkohol
Alcare Hand Degermer
Alcohol
Alcohol (USP)
Alcohol (ethyl)
Alcohol Anhydrous
Alcohol [USP]
Alcohol anhydrous
Alcohol dehydrated
Alcohol denatured
Alcohol etílico
Alcohol, Absolute
Alcohol, Dehydrated
Alcohol, Diluted
Alcohol, Grain
Alcohol, anhydrous
Alcohol, dehydrated
Alcohol, denatured
Alcohol, diluted
Alcohol, ethyl
Alcohols
Alcohols, C1-3
Alcohols, C30
Alcohols, C6-9
Alcool Ethylique
Alcool Etilico
Alcool ethylique
Alcool etilico
Alcool éthylique
Algrain
Alkohol
Alkohol [German]
Alkoholu Etylowego
Alkoholu etylowego
Aminoethanol
Anhydrol
Anhydrol PM 4085
Anhydrous alcohol
Anhydrous ethanol
Beta-Aminoethanol
Beta-Aminoethyl Alcohol
Beta-Ethanolamine
Beta-Hydroxyethylamine
C00469
C2H5OH
C2H6O
CCRIS 945
CDA 19
CDA 19-200
CHEBI:16236
CHEMBL545
CID702
Caswell No. 426
Caswell No. 430
Colamine
Cologne Spirit
Cologne spirit
Cologne spirits
 
D000431
D00068
DB00898
Dehydrated Ethanol
Dehydrated alcohol
Dehydrated ethanol
Denatured Alcohol
Denatured Alcohol Cd-10
Denatured Alcohol Cd-5
Denatured Alcohol Cd-5a
Denatured Alcohol Sd-1
Denatured Alcohol Sd-13a
Denatured Alcohol Sd-17
Denatured Alcohol Sd-23a
Denatured Alcohol Sd-28
Denatured Alcohol Sd-30
Denatured Alcohol Sd-39b
Denatured Alcohol Sd-39c
Denatured Alcohol Sd-3a
Denatured Alcohol Sd-40m
Denatured Ethanol
Denatured alcohol
Denatured ethanol
Desinfektol EL
Diluted Alcohol
Distilled spirits
E2385_SIGMA
E7023_ALDRICH
E7023_SIAL
E7148_ALDRICH
E7148_SIAL
E7517_SIGMA
EINECS 200-578-6
EINECS 270-649-4
EOH
EOX
ETA
Envision Conditioner Pdd 9020
Esumiru WK 88
EtOH
Etanolo
Etanolo [Italian]
Ethanol (9CI)
Ethanol 200 Proof
Ethanol 200 proof
Ethanol Absolute
Ethanol Absolute Bp
Ethanol Anhydrous
Ethanol Extra Pure
Ethanol Vapor
Ethanol [JAN]
Ethanol solution
Ethanol, Silent Spirit
Ethanol, undenatured
Ethanolum anhydricum
Ethicap
Ethyl Alcohol
Ethyl Alcohol & Water, 10%
Ethyl Alcohol & Water, 20%
Ethyl Alcohol & Water, 30%
Ethyl Alcohol & Water, 40%
Ethyl Alcohol & Water, 5%
Ethyl Alcohol & Water, 50%
Ethyl Alcohol & Water, 60%
Ethyl Alcohol & Water, 70%
Ethyl Alcohol & Water, 80%
Ethyl Alcohol & Water, 95%
Ethyl Alcohol & Water, 96%
Ethyl Alcohol Anhydrous
Ethyl Alcohol, Anhydrous
Ethyl Alcohol, Denatured
Ethyl Hydrate
Ethyl Hydroxide
Ethyl alc
Ethyl alcohol
Ethyl alcohol anhydrous
Ethyl alcohol in alcoholic beverages
Ethyl alcohol usp
Ethyl hydrate
Ethyl hydroxide
Ethylalcohol
Ethylalcohol [Dutch]
Ethylol
Ethylolamine
Ethyloxy Group
Etylowy alkohol
FEMA No. 2419
FEMA Number 2419
Fermentation alcohol
Glycinol
Grain alcohol
HSDB 531
HSDB 82
HYDROXYETHYL GROUP
Hinetoless
Hydroxyethane
I14-12648
IMS 99
Infinity Pure
Jaysol
Jaysol S
LS-1539
LTBB002977
Lux
Methylated Spirit Mineralised
Methylated spirit
Methylcarbinol
MolPort-001-785-844
Molasses alcohol
NCGC00091458-01
NCI-C03134
NSC 85228
NSC85228
Oxydimethylene Group
Potato alcohol
Punctilious ethyl alcohol
Pyro
QMHAIh@
Reagent Alcohol
Ru-Tuss Expectorant
SDA 3A
SDA 40-2
SDM No. 37
SY Fresh M
Sekundasprit
Silent spirit
Spirit
Spirits of wine
Spiritus vini
Spirt
Synasol
Tecsol
Tecsol C
Thanol
Thiofaco M-50
UNII-3K9958V90M
USAF EK-1597
Undenatured Ethanol
WLN: Q2
absolute alcohol
alcohol
alcohol etilico
bmse000297
etanol
ethanol
ethyl alcohol
grain alcohol
nchem.651-comp3c
nchembio.552-comp10
nchembio.94-comp20
spiritus vini
Äthanol
Äthylalkohol
éthanol
20
Melatoninapproved, nutraceutical, vet_approvedPhase 3, Phase 125573-31-4896
Synonyms:
0E2B08C1-B325-45B1-8939-6F9081EFDFA4
4-ACETAMIDO-4'-ISOTHIO-CYANATOSTILBENE-2,2'-DISULFONIC ACID
5-22-12-00042 (Beilstein Handbook Reference)
5-Methoxy-N-acetyltryptamine
5-methoxy-N-acetyltryptamine
73-31-4
A4039/0172195
AB00053279
AC1L1A9Q
AC1Q4F1W
AC1Q4F1X
AKOS000276269
Acetamide, N-(2-(5-methoxy-1H-indol-3-yl)ethyl)- (9CI)
Acetamide, N-[2-(5-methoxy-1H-indol-3-yl)ethyl]- (9CI)
Acetamide, N-[2-(5-methoxyindol-3-yl)ethyl]- (6CI,8CI)
Acetamide, {N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-}
Acetamide, {N-[2-(5-methoxyindol-3-yl)ethyl]-}
BAS 01281092
BIDD:ER0618
BPBio1_000590
BRD-K97530723-001-07-6
BRN 0205542
BSPBio_000536
BSPBio_003006
Bio-0635
C01598
CAS-73-31-4
CCRIS 3472
CHEBI:16796
CHEMBL45
CID896
ChemDiv2_003916
Circadin
D008550
D08170
DB01065
DB08189
DivK1c_000353
EINECS 200-797-7
EU-0100787
HMS1380B22
HMS1569K18
HMS1921E04
HMS2089F09
HMS501B15
HSCI1_000400
HSDB 7509
I05-0076
I10-0345
IDI1_000353
IDI1_002631
IN1244
KBio1_000353
KBio2_000665
KBio2_003233
KBio2_005801
KBio3_002226
KBioGR_000591
KBioSS_000665
L001261
LS-1623
Lopac-M-5250
Lopac0_000787
M 5250
M-1200
M-1250
M1105
M5250_SIGMA
ML1
MLS000859594
MLS001055382
MLS001240204
MT6
Mela-T
Melapure
Melatol
Melatonex
Melatonex, Melatonin
Melatonin
Melatonin (synth.) standard-grade
 
Melatonin (synth.) ultra-pure
Melatonina
Melatonina (TN)
Melatonine
Melovine
MolPort-000-737-883
N-(2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide
N-(2-(5-Methoxyindol-3-yl)ethyl)-Acetamide
N-(2-(5-Methoxyindol-3-yl)ethyl)acetamide
N-Acetyl-5-methoxy-tryptamine
N-Acetyl-5-methoxy-tryptamine Melatonine
N-Acetyl-5-methoxytryptamine
N-[2-(5-Methoxy-1H-indol-3-yl)-ethyl]-acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]-Acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]acetamide
N-[2-(5-Methoxyindol-3-yl)ethyl]-Acetamide
N-[2-(5-Methoxyindol-3-yl)ethyl]acetamide
N-[2-(5-methoxyindol-3-yl)ethyl]acetamide
N-acetyl-5-methoxy-tryptamine
NCGC00015680-01
NCGC00015680-02
NCGC00015680-03
NCGC00015680-06
NCGC00015680-13
NCGC00090727-01
NCGC00090727-02
NCGC00090727-03
NCGC00090727-04
NCGC00090727-05
NCGC00090727-06
NCGC00090727-07
NCGC00090727-08
NCGC00090727-09
NCI60_004378
NINDS_000353
NMR/14327425
NSC 113928
NSC113928
NSC56423
Nature'S Harmony
Night Rest
Oprea1_104553
Oprea1_814234
PREVENTION 1 (MELATONIN) (PREVENTION 1)
PREVENTION 2 (MELATONIN)
PREVENTION 3 (MELATONIN)
PREVENTION 4 (MELATONIN)
PREVENTION 5 (MELATONIN)
Pineal Hormone
Posidorm
Prestwick0_000458
Prestwick1_000458
Prestwick2_000458
Prestwick3_000458
Prestwick_312
Regulin
Revital Melatonin
Rx Balance
S1204_Selleck
SDCCGMLS-0065812.P001
SDCCGMLS-0065812.P002
SMP2_000309
SMR000326666
SPBio_001527
SPBio_002475
SPECTRUM1500690
STK386880
Sleep Right
Spectrum2_001344
Spectrum3_001393
Spectrum4_000066
Spectrum5_001745
Spectrum_000185
TNP00300
UNII-JL5DK93RCL
Vivitas
WLN: T56 BMJ D2MV1 GO1
ZINC00057060
{N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-} Acetamide
{N-[2-(5-methoxyindol-3-yl)ethyl]-} Acetamide
21Peripheral Nervous System AgentsPhase 322776
22Prednisolone acetatePhase 31153
23Prednisolone phosphatePhase 31153
24Neuroprotective AgentsPhase 31672
25Protective AgentsPhase 3, Phase 17190
26Prednisolone hemisuccinatePhase 31153
27Autonomic AgentsPhase 39774
28Gastrointestinal AgentsPhase 3, Phase 28109
29Anti-Inflammatory AgentsPhase 310355
30AntiemeticsPhase 33888
31glucocorticoidsPhase 34920
32Hormone AntagonistsPhase 3, Phase 212778
33Methylprednisolone acetatePhase 31153
34Methylprednisolone HemisuccinatePhase 31153
35Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 3, Phase 212767
36HormonesPhase 3, Phase 213979
37Central Nervous System DepressantsPhase 3, Phase 112806
38AntioxidantsPhase 3, Phase 12928
39Pharmaceutical SolutionsPhase 3, Phase 27793
40StrawberryNutraceuticalPhase 380
41
Propranololapproved, investigationalPhase 2216525-66-64946
Synonyms:
(+-)-Propranolol
(1)-1-(Isopropylamino)-3-(naphthyloxy)propan-2-ol
(R)-(+)-propranolol
(S)-(-)-PROPRANOLOL
1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol
1-(1-Naphthyloxy)-2-hydroxy-3-(isopropylamino)propane
1-(Isopropylamino)-3-(1-naphthoxy)-propan-2-ol
1-(Isopropylamino)-3-(1-naphthyloxy)-2-propanol
1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol
1-(naphthalen-1-yloxy)-3-(propan-2-ylamino)propan-2-ol
1-Isopropylamino-3-(1-naphthyloxy)-2-propanol
1-[(1-methylethyl)amino]-3-(naphthalen-1-yloxy)propan-2-ol
1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol
13013-17-7
2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)- (9CI)
2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-, (+-)- (9CI)
3-(naphthalen-1-yloxy)-1-(propan-2-ylamino)propan-2-ol
4199-09-1
4199-10-4
525-66-6
AB00053537
AC1L1JA4
AC1Q1QBV
AC1Q1QC0
AKOS000588816
AY 64043
AY-20694
Anaprilin
Anapriline
Angilol
Apsolol
Avlocardyl
BPBio1_001040
BRD-A10070317-003-06-9
BSPBio_000944
BSPBio_002682
Bedranol
Beprane
Berkolol
Beta Neg
Beta-Neg
Beta-Propranolol
Beta-Tablinen
Beta-Timelets
Betachron
Betadren
Betalong
Bio-0732
Bio1_000367
Bio1_000856
Bio1_001345
C07407
C16H21NO2
CBDivE_006180
CCRIS 3082
CHEBI:8499
CHEMBL27
CID4946
Cardinol
Caridolol
Corpendol
D,L-Propranolol
D08443
DB00571
DL-Propranolol hydrochloride
Deralin
DivK1c_000023
Dl-Propranolol Hydrochloride
Dociton
Duranol
EINECS 208-378-0
EINECS 235-867-6
Efektolol
Elbrol
Etalong
Euprovasin
Frekven
HMS2090L21
Herzbase
ICI 45520
IDI1_000023
INDERIDE-40/25
INDERIDE-80/25
Ikopal
Inderal
Inderal La
Inderal hydrochloride
Inderalici
Inderex
Inderide
Inderol
Indobloc
InnoPranXL
 
Innopran XL
Intermigran
KBio1_000023
KBio2_002515
KBio2_005083
KBio2_007651
KBio3_001766
KBio3_001902
KBio3_002993
KBioGR_001347
KBioGR_001684
KBioGR_002515
KBioSS_002523
Kemi
Kemi S
L000679
LS-122410
LS-184129
Lopac0_000896
Migrastat
MolPort-001-794-623
NCGC00015798-07
NCGC00024690-02
NCGC00024690-03
NINDS_000023
NSC91523
Naprilin
Obsidan
Obzidan
Oposim
Oprea1_304193
PDSP1_000767
PDSP1_001607
PDSP1_001608
PDSP2_000755
PDSP2_001591
PDSP2_001592
Prano-Puren
Pranolol
Prestwick0_000952
Prestwick1_000952
Prestwick2_000952
Prestwick3_000952
Pronovan
Propanalol
Propanix
Propanolol
Propanolol [INN-Spanish]
Prophylux
Propranalol
Propranolol
Propranolol (INN)
Propranolol (TN)
Propranolol Hcl
Propranolol Hcl Intensol
Propranolol Hydrochloride
Propranolol [INN:BAN]
Propranololo
Propranololo [DCIT]
Propranololum
Propranololum [INN-Latin]
Propranur
Proprasylyt
Pylapron
R,S-Propranolol Hydrochloride
Racemic propranolol
Rapynogen
Reducor
Reducor Line
Reducor line
SPBio_001361
SPBio_001658
SPBio_003093
STK735510
Sagittol
Sawatal
Servanolol
Sloprolol
Spectrum2_001301
Spectrum2_001699
Spectrum3_000883
Spectrum3_001071
Spectrum4_000974
Spectrum4_001222
Spectrum5_000751
Sumial
Tesnol
UNII-9Y8NXQ24VQ
b-Propranolol
beta-Propranolol
cMAP_000071
etalong
propranolol
propranololo
β-Propranolol
42
MetforminapprovedPhase 21746657-24-914219, 4091
Synonyms:
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
3-(diaminomethylidene)-1,1-dimethylguanidine
657-24-9
AC1L1HE4
AKOS000121065
Apo-Metformin
BIDD:GT0697
BPBio1_000009
BRD-K79602928-003-04-1
BSPBio_000007
BSPBio_002314
C07151
C4H11N5
CAS-1115-70-4
CCRIS 9321
CHEBI:6801
CHEMBL1431
CID4091
D04966
DB00331
DMGG
Diabetosan
Diabex
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
EINECS 211-517-8
Fluamine
Flumamine
Fortamet
Gen-Metformin
Glifage
Gliguanid
Glucophage
Glucophage XR
Glumetza
Glycon
HMS2089D19
HSCI1_000295
Haurymelin
Haurymellin
Islotin
KBio2_002310
KBio2_004878
KBio2_007446
KBio3_002790
KBioGR_002310
 
KBioSS_002312
LA-6023
LS-43899
Melbin
Metformin
Metformin (USAN/INN)
Metformin HCL
Metformin [USAN:INN:BAN]
Metformina
Metformina [DCIT]
Metformina [Spanish]
Metformine
Metformine [INN-French]
Metformine pamoate
Metforminum
Metforminum [INN-Latin]
Metiguanide
MolPort-002-929-560
MolPort-004-288-389
MolPort-005-767-418
Mylan-Metformin
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylimidodicarbonimidic diamide
N,N-dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
NCGC00016564-01
NCGC00016564-02
NCGC00016564-03
NNDG
Novo-Metformin
Nu-Metformin
PMS-Metformin
Prestwick0_000004
Prestwick1_000004
Prestwick2_000004
Prestwick3_000004
Ran-Metformin
Ratio-Metformin
Riomet
S2483_Selleck
SPBio_001928
STK011633
Sandoz Metformin
Siofor
T5895664
Teva-Metformin
UNII-9100L32L2N
ZINC12859773
cMAP_000016
metformin
metformin hydrochloride
43
SimvastatinapprovedPhase 1, Phase 251079902-63-954454
Synonyms:
(+)-Simvastatin
(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate
2,2-Dimethylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester
2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
79902-63-9
AC-1530
AC1L1H1F
AKOS005111006
ARONIS24119
BCBcMAP01_000007
BIDD:GT0769
BPBio1_001001
BRD-K22134346-001-05-8
BRN 4768037
BSPBio_000909
BSPBio_002337
Bio-0672
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,*aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester
C25H38O5
CCRIS 7558
CHEBI:9150
CHEMBL1064
CID54454
CPD000718785
Cholestat
Coledis
Colemin
Corolin
D00434
D019821
DRG-0320
Denan
DivK1c_006991
Eucor
HMS1570N11
HMS1922H13
HMS2089D12
HMS2093E06
HSDB 7208
InChI=1/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1
KBio1_001935
KBio2_002197
KBio2_004765
KBio2_007333
KBio3_001557
KBioGR_001244
KBioSS_002197
KS-1113
Kolestevan
L 644128-000U
LS-46264
Labistatin
Lipex
Lipinorm
Liponorm
Lipovas
Lodales
MK 0733
MK 733
MK-0733
MK-733
MK733
MLS001304029
MLS001333077
MLS001333078
 
MLS002154038
Medipo
Modutrol
MolPort-002-507-345
MolPort-002-885-862
NCGC00017324-01
NCGC00017324-02
NCGC00017324-03
Nivelipol
Nor-Vastina
Pantok
Pepstatin
Prestwick0_000865
Prestwick1_000865
Prestwick2_000865
Prestwick3_000865
Prestwick_171
Rechol
Rendapid
S1792_Selleck
S6196_SIGMA
SAM002589969
SMR000718785
SPBio_001881
SPBio_002830
SPECTRUM1504236
STK801938
Simcor
Simovil
Simvast CR
Simvastatin
Simvastatin & Primycin
Simvastatin (JAN/USP/INN)
Simvastatin [USAN:INN:BAN]
Simvastatin [Usan:Ban:Inn]
Simvastatin lactone
Simvastatin, Compactin
Simvastatina
Simvastatina [Spanish]
Simvastatine
Simvastatine [French]
Simvastatinum
Simvastatinum [Latin]
Simvotin
Sinvacor
Sinvascor
Sivastin
SpecPlus_000895
Spectrum2_001671
Spectrum3_000669
Spectrum4_000632
Spectrum5_001428
Spectrum_001717
Statin
Synvinolin
TNP00259
UNII-AGG2FN16EV
Valemia
Vasotenal
Velostatin
Vytorin
ZINC03780893
Zocor
Zocor (TN)
Zocor, Simlup, Simcard, Simvacor, Simvoget, Zorced, Simvastatin
Zocord
[(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate
butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1S-[1 alpha,3 alpha,7 beta,8 beta(2S*,4S*),-8a beta
nchembio790-comp16
simvastatin
44
Letrozoleapproved, investigationalPhase 2382112809-51-53902
Synonyms:
1-[Bis-(4-cyanophenyl)methyl]-1,2,4-triazole
1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole
112809-51-5
4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile
4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile
4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile)
4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile
4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-Benzonitrile Letrozole
4,4'-(1h-1,2,4-triazol-1-ylmethylene) bis-benzonitrile
4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-benzonitrile
4,4'-(1h-1,2,4-triazol-1-ylmethylene)bisbenzonitrile
4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile
AB00514009
AC-1193
AC1L1GYT
AKOS005145822
BIDD:GT0015
BIDD:PXR0130
BPBio1_001331
BRD-K88789588-001-03-2
BSPBio_001209
Bio-0057
C067431
C08163
C17H11N5
CAS-112809-51-5
CCRIS 8822
CGS 20267
CGS 20267, Femara, Piroxicam, Letrozole
CGS-20267
CHEBI:6413
CHEMBL1444
CID3902
CPD000466343
D00964
 
DB01006
FEM-345
Femara
Femara (TN)
Femera
HMS1571M11
HMS2051E08
HMS2089L22
HSDB 7461
I06-0022
LS-38788
Letoval
Letrozol
Letrozole
Letrozole (JAN/USP/INN)
Letrozole [USAN:INN]
MLS000759455
MLS001424038
MLS002584991
MolPort-003-848-373
NCGC00016973-01
NCGC00016973-02
NSC719345
Novartis Brand of Letrozole
Prestwick0_001025
Prestwick1_001025
Prestwick2_001025
Prestwick3_001025
S1235_Selleck
SAM001246649
SMR000466343
SPBio_003070
TL8000371
UNII-7LKK855W8I
ZINC03778874
letrozole
45
Octreotideapproved, investigationalPhase 221383150-76-9383414, 6400441
Synonyms:
(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaa
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
79517-01-4 (acetate salt)
83150-76-9
AC1L1GVU
AC1L8LCD
AC1L9M4X
C07306
C5H12O2.C4H10
CHEBI:427278
CHEBI:611465
CHEMBL1680
CID383414
CID448601
CID54374
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide
D00442
DRG-0115
HMS2090C09
HS-2020
 
L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide, (R-(R*
L000453
LS-177735
LS-187135
Longastatin
NCGC00181796-01
NCI60_025753
Octreotida
Octreotida [Spanish]
Octreotide
Octreotide (USAN/INN)
Octreotide Acetate Salt
Octreotide [USAN:INN:BAN]
Octreotide-LAR
Octreotidum
Octreotidum [Latin]
Octrotide
SAN 201-995
SM 201-995
SMS 201-995
SMS-201-995
Sandostatine
Sandoz 201-995
UNII-RWM8CCW8GP
nchembio.184-comp3
zacycloicosane-4-carboxamide acetate
46
OlaparibapprovedPhase 2126763113-22-023725625
Synonyms:
4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-one
4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one
4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
763113-22-0
937799-91-2
AKOS005145764
AZD 2281
AZD-2281
AZD2281
 
Acylpiperazine analogue, 47
CHEMBL521686
EC-000.2324
EN002690
FT-0083489
KU-0059436
KU-59436
Olaparib
Olaparib, KU-0059436, AZD2281, KU0059436, AZD2281
S1060_Selleck
olaparib
47
Sorafenibapproved, investigationalPhase 2692284461-73-0216239, 406563
Synonyms:
284461-73-0
4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide
4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE
AB1004622
AC-1674
AC1L50CF
BAX
BAY 43-9006
BAY 43-9006 (free base)
BAY 43-9006 tosylate salt
BAY 439006
BAY 54-9085 (tosylate salt)
BAY-43-0006
BAY-43-9006
BAY-54-9085
BAY43-9006
BRD-K23984367-001-01-8
Bio-0100
CHEBI:47228
CHEBI:50924
CHEMBL1336
CID216239
 
D08524
DB00398
DB07438
EN002709
I06-0856
K00597a
Kinome_766
LS-186067
LS-187021
LS-187788
MolPort-003-850-270
N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea
N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea
NCGC00167488-01
NSC-724772
NSC747971
Nexavar
STK627350
Sorafenib
Sorafenib (INN)
Sorafenib [INN]
Sorafenib tosylate
Sorafenibum
UNII-9ZOQ3TZI87
ZINC01493878
nchembio.117-comp17
sorafenib
sorafenibum
48
Lapatinibapproved, investigational, Approved March 2007Phase 2296231277-92-2, 388082-78-8208908, 9941095
Synonyms:
1xkk
231277-92-2
388082-78-8
4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline
AB1004631
AC-1314
AC1L4LL4
AKOS005145766
CHEBI:49603
CHEMBL1201179
CHEMBL554
CID11557040
CID208908
D04024
D08108
DB01259
DB02584
EN002712
FMM
GSK 572016
GSK572016
GW 572016
GW 572016X
GW-2016
GW-572016
GW-572016F
GW2016
GW572016
HMS2089H10
I01-1247
 
Kinome_3684
Kinome_3685
LAPATINIB DITOSYLATE MONOHYDRATE
LS-187029
LS-187771
Lapatinib
Lapatinib (INN)
Lapatinib Ditosylate
Lapatinib [INN]
Lapatinib ditosylate
Lapatinib ditosylate (USAN)
Lapatinib tosilate hydrate
Lapatinib tosilate hydrate (JAN)
Lapatinib, Tykerb, GW572016
N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine
N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine
N-(3-chloro-4-((3-Fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine
N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE
N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
NCGC00167507-01
NSC745750
TL80090051
Tycerb
Tykerb
Tykerb (TN)
Tyverb
UNII-0VUA21238F
lapatinib
lapatinib ditosylate
nchembio866-comp20
49Adrenergic AgentsPhase 25140
50Adrenergic AntagonistsPhase 21535

Interventional clinical trials:

(show top 50)    (show all 61)
idNameStatusNCT IDPhase
1Rapamycin In Angiomyolipomas In Patients With Tuberous SclerosisCompletedNCT01217125Phase 4
2Doxycycline In Lymphangioleiomyomatosis (LAM)CompletedNCT00989742Phase 4
3Long-term Follow-up for Growth and Development of Pediatric Patients From CRAD001M2301Active, not recruitingNCT02338609Phase 4
4Sabril for Complex Partial Seizures in Adult Tolerability Study (TS) PatientsTerminatedNCT01266291Phase 4
5Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous MethylprednisoloneUnknown statusNCT00004645Phase 3
6Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1)CompletedNCT00789828Phase 3
7Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)CompletedNCT00790400Phase 3
8Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis ComplexRecruitingNCT01730209Phase 2, Phase 3
9A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)RecruitingNCT02544763Phase 3
10A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset SeizuresActive, not recruitingNCT01713946Phase 3
11Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment DisabilitiesActive, not recruitingNCT01906866Phase 3
12An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)Enrolling by invitationNCT02544750Phase 3
13Long-term Trial of Topical Sirolimus to Angiofibroma in Patient With Tuberous Sclerosis ComplexNot yet recruitingNCT02634931Phase 3
14Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC)Not yet recruitingNCT02635789Phase 3
15Topical Everolimus in Patients With Tuberous Sclerosis ComplexNot yet recruitingNCT02860494Phase 2, Phase 3
16Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued TreatmentNot yet recruitingNCT02962414Phase 3
17Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAMUnknown statusNCT00490789Phase 2
18Sirolimus in Treating Patients With Angiomyolipoma of the KidneyUnknown statusNCT00126672Phase 2
19Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAMCompletedNCT00457808Phase 2
20Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC)CompletedNCT01289912Phase 2
21Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis ComplexCompletedNCT00411619Phase 1, Phase 2
22Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)CompletedNCT01070316Phase 1, Phase 2
23Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM)CompletedNCT00792766Phase 1, Phase 2
24RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAMCompletedNCT00457964Phase 1, Phase 2
25Topical Rapamycin to Erase Angiofibromas in TSCCompletedNCT01526356Phase 2
26Rapalogues for Autism Phenotype in TSC: A Feasibility StudyCompletedNCT01929642Phase 2
27A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous SclerosisRecruitingNCT01954693Phase 2
28Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockersRecruitingNCT02104011Phase 2
29Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis ComplexRecruitingNCT02849457Phase 2
30Safety of Simvastatin in LAM and TSCRecruitingNCT02061397Phase 1, Phase 2
31A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCDRecruitingNCT02451696Phase 2
32Everolimus for Cancer With TSC1 or TSC2 MutationRecruitingNCT02201212Phase 2
33Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial CancerRecruitingNCT02188550Phase 2
34Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETsRecruitingNCT02294006Phase 2
35Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 MutationsRecruitingNCT02352844Phase 2
36OLAParib COmbinationsRecruitingNCT02576444Phase 2
37Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: My Own Specific TreatmentRecruitingNCT02029001Phase 2
38A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComaWithdrawnNCT01690871Phase 2
39Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)CompletedNCT01031901Phase 1
40Tuberous Sclerosis Complex: Facial Angiofibroma Skin CreamCompletedNCT01853423Phase 1
41Assessment of the Pharmacokinetics of Circadin® in Children With Neurodevelopmental Disorders and Sleep DisturbancesCompletedNCT01903681Phase 1
42A Phase I Study of BKM120 and Everolimus in Advanced Solid MalignanciesRecruitingNCT01470209Phase 1
43Tuberous Sclerosis Complex Natural History Study: Renal ManifestationsUnknown statusNCT00598455
44Effect of Fasting on the Size of Abdominal Lymphatic Tumors in WomenCompletedNCT00552955
45Evaluation of New Biomarkers Predictive of Efficacy Betablockers in PEComa and Vascular Pediatric TumorsCompletedNCT02334930
46Official Record of Patients Diagnosed With Lymphangioleiomyomatosis (LAM)CompletedNCT00001869
47Early Biomarkers of Autism in Infants With Tuberous Sclerosis Complex (TSC)RecruitingNCT01780441
48Genetic Heterogeneity and Genotype-phenotype Correlation of Children and Adults With Tuberous Sclerosis ComplexRecruitingNCT02654340
49Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)RecruitingNCT02461459
50Study of Skin Tumors in Tuberous SclerosisRecruitingNCT00001975

Search NIH Clinical Center for Tuberous Sclerosis-1


Cochrane evidence based reviews: tuberous sclerosis

Genetic Tests for Tuberous Sclerosis-1

About this section

Genetic tests related to Tuberous Sclerosis-1:

id Genetic test Affiliating Genes
1 Tuberous Sclerosis 126 24 TSC1
2 Tuberous Sclerosis Syndrome26
3 Tuberous Sclerosis Complex24 TSC2

Anatomical Context for Tuberous Sclerosis-1

About this section

MalaCards organs/tissues related to Tuberous Sclerosis-1:

35
Skin, Kidney, Brain, Heart, Lung, Eye, Pancreas

Animal Models for Tuberous Sclerosis-1 or affiliated genes

About this section

MGI Mouse Phenotypes related to Tuberous Sclerosis-1:

40 (show all 25)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053709.0CDKN1B, NF1, PKD1, PKHD1, PTEN, TSC1
2MP:00053889.0CDKN1B, MTOR, NF1, PKD1, PKHD1, PTEN
3MP:00053678.6CDKN1B, MTOR, NF1, PKD1, PKHD1, PTEN
4MP:00053758.5CDKN1B, DBH, EIF4EBP1, MTOR, PKD1, PTEN
5MP:00020068.4CDKN1B, NF1, PKD1, PTEN, RPS6KB1, TSC1
6MP:00107718.2CDKN1B, COL5A1, DBH, NF1, PKD1, PTEN
7MP:00053898.2CDKN1B, DCX, PKD1, PKHD1, PTEN, RPS6KB1
8MP:00053697.6CDKN1B, GFAP, MTOR, NF1, PKD1, PTEN
9MP:00053807.5COL5A1, MTOR, NF1, PKD1, PTEN, RHEB
10MP:00053867.5CDKN1B, DBH, DCX, GFAP, MTOR, NF1
11MP:00053797.5CDKN1B, DBH, MTOR, NF1, PKD1, PKHD1
12MP:00028737.1COL5A1, DBH, GFAP, MTOR, NF1, PKD1
13MP:00053877.1CDKN1B, GFAP, MTOR, NF1, PKD1, PKHD1
14MP:00036316.4CDKN1B, DBH, DCX, GFAP, MTOR, NF1
15MP:00053846.2CDKN1B, EIF4EBP1, GFAP, MTOR, NF1, PKD1
16MP:00053766.2CDKN1B, DBH, EIF4EBP1, GFAP, MTOR, NF1
17MP:00053855.3CDKN1B, COL5A1, DBH, EIF4EBP1, GFAP, NF1
18MP:00053785.2CDKN1B, COL5A1, DBH, DCX, EIF4EBP1, GFAP
19MP:00107684.9CDKN1B, COL5A1, DBH, DCX, EIF4EBP1, GFAP

Publications for Tuberous Sclerosis-1

About this section

Articles related to Tuberous Sclerosis-1:

idTitleAuthorsYear
1
The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination. (11175345)
2000

Variations for Tuberous Sclerosis-1

About this section

UniProtKB/Swiss-Prot genetic disease variations for Tuberous Sclerosis-1:

69
id Symbol AA change Variation ID SNP ID
1TSC1p.Leu191HisVAR_009399rs118203403
2TSC1p.Met224ArgVAR_009401rs118203426
3TSC1p.Gln654GluVAR_009407rs75820036
4TSC1p.Ala726GluVAR_009408rs118203655
5TSC1p.Thr899SerVAR_009412rs76801599
6TSC1p.Leu72ProVAR_054387rs118203354
7TSC1p.Arg500GlnVAR_054391rs118203538
8TSC1p.Leu117ProVAR_070637rs118203368
9TSC1p.Leu180ProVAR_070643rs118203396

Clinvar genetic disease variations for Tuberous Sclerosis-1:

5 (show all 123)
id Gene Variation Type Significance SNP ID Assembly Location
1TSC2NM_000548.4(TSC2): c.4642delC (p.Leu1548Cysfs)deletionPathogenicrs137854083GRCh37Chr 16, 2135303: 2135303
2TSC2NM_000548.4(TSC2): c.5024C> T (p.Pro1675Leu)SNVPathogenicrs45483392GRCh37Chr 16, 2137898: 2137898
3TSC2NM_000548.4(TSC2): c.34A> T (p.Lys12Ter)SNVPathogenicrs45512692GRCh37Chr 16, 2098650: 2098650
4TSC2NM_000548.4(TSC2): c.2056_2059dupTACT (p.Ser687Leufs)duplicationPathogenicrs137854337GRCh37Chr 16, 2121894: 2121897
5TSC2NM_000548.4(TSC2): c.1513C> T (p.Arg505Ter)SNVPathogenicrs45517179GRCh37Chr 16, 2114342: 2114342
6TSC2NM_000548.4(TSC2): c.1832G> A (p.Arg611Gln)SNVPathogenicrs28934872GRCh37Chr 16, 2120572: 2120572
7TSC2NM_000548.4(TSC2): c.2150T> G (p.Leu717Arg)SNVPathogenicrs45517214GRCh37Chr 16, 2122294: 2122294
8TSC2NM_000548.4(TSC2): c.1432C> T (p.Gln478Ter)SNVPathogenicrs121964862GRCh37Chr 16, 2113043: 2113043
9TSC2NM_000548.4(TSC2): c.4508A> C (p.Gln1503Pro)SNVPathogenicrs45516293GRCh37Chr 16, 2134966: 2134966
10TSC2NM_000548.4(TSC2): c.5238_5255del18 (p.His1746_Arg1751del)deletionPathogenicrs137854218GRCh37Chr 16, 2138305: 2138322
11TSC2NM_000548.4(TSC2): c.2714G> A (p.Arg905Gln)SNVPathogenicrs45517259GRCh37Chr 16, 2126143: 2126143
12TSC2NM_000548.4(TSC2): c.2713C> T (p.Arg905Trp)SNVPathogenicrs45517258GRCh37Chr 16, 2126142: 2126142
13TSC2NM_000548.4(TSC2): c.2713C> G (p.Arg905Gly)SNVPathogenicrs45517258GRCh37Chr 16, 2126142: 2126142
14TSC2NM_000548.4(TSC2): c.2355+2_2355+5delTAGGdeletionPathogenicrs137854250GRCh37Chr 16, 2122986: 2122989
15TSC2NM_000548.4(TSC2): c.1322G> A (p.Trp441Ter)SNVPathogenicrs45515894GRCh37Chr 16, 2112562: 2112562
16TSC1NM_000368.4(TSC1): c.2515_2518delGAGT (p.Glu839Argfs)deletionPathogenicrs794727320GRCh37Chr 9, 135776209: 135776212
17TSC1NM_000368.4(TSC1): c.2675_2676delGA (p.Arg892Lysfs)deletionPathogenicrs118203726GRCh38Chr 9, 132897560: 132897561
18TSC1NM_000368.4(TSC1): c.1530_1531delCA (p.Asp510Glufs)deletionPathogenicrs118203544GRCh37Chr 9, 135781434: 135781435
19TSC1NM_000368.4(TSC1): c.1998-1G> TSNVLikely pathogenicrs118203614GRCh37Chr 9, 135779842: 135779842
20TSC1NM_000368.4(TSC1): c.1152delA (p.Gly385Glufs)deletionPathogenicrs118203501GRCh37Chr 9, 135786069: 135786069
21TSC1NM_000368.4(TSC1): c.1257delC (p.Arg420Glyfs)deletionPathogenicrs118203506GRCh37Chr 9, 135785964: 135785964
22TSC1NM_000368.4(TSC1): c.1431_1434delAGAA (p.Glu478Lysfs)deletionPathogenicrs118203527GRCh37Chr 9, 135782122: 135782125
23TSC1NM_000368.4(TSC1): c.1498C> T (p.Arg500Ter)SNVPathogenicrs118203537GRCh37Chr 9, 135781467: 135781467
24TSC1NM_000368.4(TSC1): c.1525C> T (p.Arg509Ter)SNVPathogenicrs118203542GRCh37Chr 9, 135781440: 135781440
25TSC1NM_000368.4(TSC1): c.1580_1581delAG (p.Gln527Argfs)deletionPathogenicrs118203550GRCh37Chr 9, 135781384: 135781385
26TSC1NM_000368.4(TSC1): c.1959dupA (p.Gln654Thrfs)duplicationPathogenicrs118203603GRCh37Chr 9, 135781006: 135781006
27TSC1NM_000368.4(TSC1): c.1963C> T (p.Gln655Ter)SNVPathogenicrs118203606GRCh37Chr 9, 135781002: 135781002
28TSC1NM_000368.4(TSC1): c.1997+1G> ASNVPathogenicrs118203610GRCh37Chr 9, 135780967: 135780967
29TSC1NM_000368.4(TSC1): c.2074C> T (p.Arg692Ter)SNVPathogenicrs118203631GRCh37Chr 9, 135779172: 135779172
30TSC1NM_000368.4(TSC1): c.211-2A> CSNVPathogenicrs118203352GRCh37Chr 9, 135801128: 135801128
31TSC1NM_000368.4(TSC1): c.2356C> T (p.Arg786Ter)SNVPathogenicrs118203682GRCh37Chr 9, 135778027: 135778027
32TSC1NM_000368.4(TSC1): c.2509_2512delAACA (p.Asn837Valfs)deletionPathogenicrs118203707GRCh37Chr 9, 135776215: 135776218
33TSC1NM_000368.4(TSC1): c.2569delG (p.Glu857Argfs)deletionPathogenicrs118203712GRCh37Chr 9, 135776158: 135776158
34TSC1NM_000368.4(TSC1): c.2689C> T (p.Gln897Ter)SNVPathogenicrs118203727GRCh37Chr 9, 135772934: 135772934
35TSC1NM_000368.4(TSC1): c.271_272delTC (p.Ser91Valfs)deletionPathogenicrs118203360GRCh37Chr 9, 135801065: 135801066
36TSC1NM_000368.4(TSC1): c.491G> A (p.Trp164Ter)SNVPathogenicrs118203387GRCh37Chr 9, 135798752: 135798752
37TSC1NM_000368.4(TSC1): c.664-1G> ASNVPathogenicrs118203423GRCh37Chr 9, 135796824: 135796824
38TSC1NM_000368.4(TSC1): c.664-1G> CSNVPathogenicrs118203423GRCh37Chr 9, 135796824: 135796824
39TSC1NM_000368.4(TSC1): c.682C> T (p.Arg228Ter)SNVPathogenicrs118203427GRCh37Chr 9, 135796805: 135796805
40TSC1NM_000368.4(TSC1): c.733C> T (p.Arg245Ter)SNVPathogenicrs118203434GRCh37Chr 9, 135796754: 135796754
41TSC1NM_000368.4(TSC1): c.737+1G> ASNVPathogenicrs118203438GRCh37Chr 9, 135796749: 135796749
42TSC1NM_000368.4(TSC1): c.812_813delAT (p.Tyr271Terfs)deletionPathogenicrs118203451GRCh37Chr 9, 135787769: 135787770
43TSC1NM_000368.4(TSC1): c.901_902delCA (p.Gln301Glufs)deletionPathogenicrs118203464GRCh37Chr 9, 135787680: 135787681
44TSC1NM_000368.4(TSC1): c.973C> T (p.Gln325Ter)SNVPathogenicrs118203474GRCh37Chr 9, 135786896: 135786896
45TSC1NM_000368.4(TSC1): c.989_990delTG (p.Leu330Glnfs)deletionPathogenicrs118203479GRCh37Chr 9, 135786879: 135786880
46TSC1NM_000368.4(TSC1): c.989dupT (p.Ser331Glufs)duplicationPathogenicrs118203478GRCh37Chr 9, 135786880: 135786880
47TSC2NM_000548.4(TSC2): c.1372C> T (p.Arg458Ter)SNVPathogenicrs45517169GRCh37Chr 16, 2112983: 2112983
48TSC2NM_000548.4(TSC2): c.226-2A> GSNVPathogenicrs45517096GRCh37Chr 16, 2103341: 2103341
49TSC2NM_000548.4(TSC2): c.2356-2A> CSNVPathogenicrs45517229GRCh37Chr 16, 2124199: 2124199
50TSC2NM_000548.4(TSC2): c.3094C> T (p.Arg1032Ter)SNVPathogenicrs45465195GRCh37Chr 16, 2129160: 2129160
51TSC2NM_000548.4(TSC2): c.3206_3207delTG (p.Val1069Aspfs)deletionPathogenicrs137854076GRCh37Chr 16, 2129351: 2129352
52TSC2NM_000548.4(TSC2): c.3412C> T (p.Arg1138Ter)SNVPathogenicrs45451497GRCh37Chr 16, 2130180: 2130180
53TSC2NM_000548.4(TSC2): c.352dupG (p.Val118Glyfs)duplicationPathogenicrs137853982GRCh37Chr 16, 2104312: 2104312
54TSC2NM_000548.4(TSC2): c.4115_4116delTG (p.Val1372Glyfs)deletionPathogenicrs137854368GRCh37Chr 16, 2134338: 2134339
55TSC2NM_000548.4(TSC2): c.4544_4547delACAA (p.Asn1515Serfs)deletionPathogenicrs137854175GRCh37Chr 16, 2135002: 2135005
56TSC2NM_000548.4(TSC2): c.4573C> T (p.Gln1525Ter)SNVPathogenicrs45517352GRCh37Chr 16, 2135234: 2135234
57TSC2NM_000548.4(TSC2): c.4829G> A (p.Trp1610Ter)SNVPathogenicrs45517371GRCh37Chr 16, 2136360: 2136360
58TSC2NM_000548.4(TSC2): c.4842_4844delCAT (p.Ile1614del)deletionPathogenicrs137854331GRCh37Chr 16, 2136373: 2136375
59TSC2NM_000548.4(TSC2): c.4952A> G (p.Asn1651Ser)SNVPathogenicrs45517382GRCh37Chr 16, 2136835: 2136835
60TSC2NM_000548.4(TSC2): c.4993C> T (p.Gln1665Ter)SNVPathogenicrs45448101GRCh37Chr 16, 2137867: 2137867
61TSC2NM_000548.4(TSC2): c.5150T> C (p.Leu1717Pro)SNVPathogenicrs45517398GRCh37Chr 16, 2138130: 2138130
62TSC2NM_000548.4(TSC2): c.5219G> A (p.Trp1740Ter)SNVPathogenicrs137854219GRCh37Chr 16, 2138286: 2138286
63TSC2NM_000548.4(TSC2): c.5252_5259+19del27deletionPathogenicrs137854397GRCh37Chr 16, 2138319: 2138345
64TSC2NM_000548.4(TSC2): c.5254C> T (p.Gln1752Ter)SNVPathogenicrs45517414GRCh37Chr 16, 2138321: 2138321
65TSC2NM_000548.4(TSC2): c.646G> T (p.Glu216Ter)SNVPathogenicrs45517118GRCh37Chr 16, 2106243: 2106243
66TSC2NM_000548.4(TSC2): c.976-15G> ASNVPathogenicrs45517150GRCh37Chr 16, 2110656: 2110656
67TSC2NM_000548.4(TSC2): c.648+1G> ASNVPathogenicrs45488893GRCh37Chr 16, 2106246: 2106246
68TSC2NM_000548.4(TSC2): c.5259+1delGdeletionPathogenicrs137854317GRCh37Chr 16, 2138327: 2138327
69TSC2NM_000548.4(TSC2): c.5160+1G> ASNVPathogenicrs45517399GRCh37Chr 16, 2138141: 2138141
70TSC2NM_000548.4(TSC2): c.826_827delAT (p.Met276Valfs)deletionPathogenicrs137853977GRCh37Chr 16, 2107157: 2107158
71TSC2NM_000548.4(TSC2): c.4989+1G> ASNVPathogenicrs45517386GRCh37Chr 16, 2136873: 2136873
72TSC2NM_000548.4(TSC2): c.5227C> T (p.Arg1743Trp)SNVPathogenicrs45517412GRCh37Chr 16, 2138294: 2138294
73TSC2NM_000548.4(TSC2): c.4318C> T (p.Gln1440Ter)SNVPathogenicrs45517337GRCh37Chr 16, 2134541: 2134541
74TSC2NM_000548.4(TSC2): c.3696dupT (p.Asn1233Terfs)duplicationPathogenicrs137854210GRCh37Chr 16, 2131681: 2131681
75TSC2NM_000548.4(TSC2): c.4096G> T (p.Glu1366Ter)SNVPathogenicrs45517327GRCh37Chr 16, 2134319: 2134319
76TSC2NM_000548.4(TSC2): c.2666C> T (p.Ala889Val)SNVPathogenicrs137854155GRCh37Chr 16, 2126095: 2126095
77TSC2NM_000548.4(TSC2): c.2690T> C (p.Phe897Ser)SNVPathogenicrs45517255GRCh37Chr 16, 2126119: 2126119
78TSC2NM_000548.4(TSC2): c.1760_1761delAT (p.Tyr587Terfs)deletionPathogenicrs137854371GRCh37Chr 16, 2120500: 2120501
79TSC2NM_000548.4(TSC2): c.1444-2A> GSNVPathogenicrs45517174GRCh37Chr 16, 2114271: 2114271
80TSC2NM_000548.4(TSC2): c.1831C> T (p.Arg611Trp)SNVPathogenicrs45469298GRCh37Chr 16, 2120571: 2120571
81TSC2NM_000548.4(TSC2): c.1599+1G> ASNVPathogenicrs45517182GRCh37Chr 16, 2114429: 2114429
82TSC2NM_000548.4(TSC2): c.2328C> A (p.Tyr776Ter)SNVPathogenicrs45517225GRCh37Chr 16, 2122957: 2122957
83TSC2NM_000548.4(TSC2): c.2071delC (p.Arg691Alafs)deletionPathogenicrs137854071GRCh37Chr 16, 2121909: 2121909
84TSC2NM_000548.4(TSC2): c.2410T> C (p.Cys804Arg)SNVLikely pathogenic, Pathogenicrs137853995GRCh37Chr 16, 2124255: 2124255
85TSC2NM_000548.4(TSC2): c.2098-1G> ASNVPathogenicrs45517212GRCh37Chr 16, 2122241: 2122241
86TSC2NM_000548.4(TSC2): c.2108G> A (p.Trp703Ter)SNVPathogenicrs45517213GRCh37Chr 16, 2122252: 2122252
87TSC2NM_000548.4(TSC2): c.268C> T (p.Gln90Ter)SNVPathogenicrs45517099GRCh37Chr 16, 2103385: 2103385
88TSC2NM_000548.4(TSC2): c.3598C> T (p.Arg1200Trp)SNVPathogenicrs45438205GRCh37Chr 16, 2130366: 2130366
89TSC2NM_000548.4(TSC2): c.2546-2A> GSNVPathogenicrs45517246GRCh37Chr 16, 2125798: 2125798
90TSC2NM_000548.4(TSC2): c.4223delG (p.Gly1408Alafs)deletionPathogenicrs137854427GRCh37Chr 16, 2134446: 2134446
91TSC2NM_000548.4(TSC2): c.496C> T (p.Gln166Ter)SNVPathogenicrs45517111GRCh37Chr 16, 2105417: 2105417
92TSC2NM_000548.4(TSC2): c.2639+1G> CSNVPathogenicrs45517252GRCh37Chr 16, 2125894: 2125894
93TSC2NM_000548.4(TSC2): c.4912_4914delAAG (p.Lys1638del)deletionPathogenicrs137854261GRCh37Chr 16, 2136795: 2136797
94TSC2NM_000548.4(TSC2): c.848+1G> ASNVPathogenicrs45466296GRCh37Chr 16, 2107180: 2107180
95TSC2NM_000548.4(TSC2): c.5138G> A (p.Arg1713His)SNVPathogenicrs45517395GRCh37Chr 16, 2138118: 2138118
96TSC2NM_000548.4(TSC2): c.5170C> T (p.Gln1724Ter)SNVPathogenicrs45472701GRCh37Chr 16, 2138237: 2138237
97TSC2NM_000548.4(TSC2): c.5228G> A (p.Arg1743Gln)SNVPathogenicrs45507199GRCh37Chr 16, 2138295: 2138295
98TSC2NM_000548.4(TSC2): c.4934_4935delTT (p.Phe1645Cysfs)deletionPathogenicrs137854249GRCh37Chr 16, 2136817: 2136818
99TSC2NM_000548.4(TSC2): c.4375C> T (p.Arg1459Ter)SNVPathogenicrs45517340GRCh37Chr 16, 2134598: 2134598
100TSC2NM_000548.4(TSC2): c.569dupA (p.Tyr190Terfs)duplicationPathogenicrs137854359GRCh37Chr 16, 2105490: 2105490
101TSC2NM_000548.4(TSC2): c.3106T> C (p.Ser1036Pro)SNVPathogenicrs45517281GRCh37Chr 16, 2129172: 2129172
102TSC2NM_000548.4(TSC2): c.4180_4181delCT (p.Leu1394Alafs)deletionPathogenicrs137854363GRCh37Chr 16, 2134403: 2134404
103TSC2NM_000548.4(TSC2): c.3397+5G> ASNVPathogenicrs45501492GRCh37Chr 16, 2129675: 2129675
104TSC2NM_000548.4(TSC2): c.3401delG (p.Gly1134Alafs)deletionPathogenicrs137854314GRCh37Chr 16, 2130169: 2130169
105TSC2NM_000548.4(TSC2): c.4762C> T (p.Gln1588Ter)SNVPathogenicrs45479192GRCh37Chr 16, 2136293: 2136293
106TSC2NM_000548.4(TSC2): c.2251C> T (p.Arg751Ter)SNVPathogenicrs45517222GRCh37Chr 16, 2122880: 2122880
107TSC2NM_000548.4(TSC2): c.1255C> T (p.Pro419Ser)SNVPathogenicrs45517159GRCh37Chr 16, 2112007: 2112007
108TSC1NM_000368.4(TSC1): c.1888_1891delAAAG (p.Lys630Glnfs)deletionPathogenicrs118203595GRCh37Chr 9, 135781074: 135781077
109TSC1NM_000368.4(TSC1): c.749T> A (p.Leu250Ter)SNVPathogenicrs118203447GRCh37Chr 9, 135787833: 135787833
110TSC1NM_000368.4(TSC1): c.1904_1905delCA (p.Thr635Argfs)deletionPathogenicrs118203597GRCh37Chr 9, 135781060: 135781061
111TSC1NM_000368.4(TSC1): c.671T> G (p.Met224Arg)SNVPathogenicrs118203426GRCh37Chr 9, 135796816: 135796816
112TSC1NM_000368.4(TSC1): c.539T> C (p.Leu180Pro)SNVPathogenicrs118203396GRCh37Chr 9, 135797330: 135797330
113TSC1NM_000368.4(TSC1): c.260T> G (p.Leu87Ter)SNVPathogenicrs397514776GRCh37Chr 9, 135801077: 135801077
114TSC1NM_000368.4(TSC1): c.1680_1702del23 (p.Ser561Argfs)deletionPathogenicrs118203557GRCh37Chr 9, 135781263: 135781285
115TSC1NM_000368.4(TSC1): c.2041+1G> ASNVPathogenicrs397514842GRCh37Chr 9, 135779797: 135779797
116TSC1NM_000368.4(TSC1): c.866C> G (p.Ser289Ter)SNVPathogenicrs397514867GRCh37Chr 9, 135787716: 135787716
117TSC1NM_000368.4(TSC1): c.2698C> T (p.Gln900Ter)SNVPathogenicrs397514871GRCh37Chr 9, 135772925: 135772925
118TSC1NM_000368.4(TSC1): c.2672delA (p.Asn891Thrfs)deletionPathogenicrs397514875GRCh37Chr 9, 135772951: 135772951
119TSC2NM_000548.4(TSC2): c.1447G> T (p.Glu483Ter)SNVPathogenicrs397515297GRCh37Chr 16, 2114276: 2114276
120TSC2NM_000548.4(TSC2): c.2688G> A (p.Trp896Ter)SNVPathogenicrs397514913GRCh37Chr 16, 2126117: 2126117
121TSC2NM_000548.4(TSC2): c.4147_4163dup17 (p.Pro1389Alafs)duplicationPathogenicrs397515009GRCh37Chr 16, 2134370: 2134386
122TSC2NM_000548.4(TSC2): c.3236C> A (p.Ser1079Ter)SNVPathogenicrs397515087GRCh37Chr 16, 2129381: 2129381
123TSC2NM_000548.4(TSC2): c.1959_1960delAG (p.Gly654Leufs)deletionPathogenicrs397515226GRCh37Chr 16, 2121797: 2121798

Copy number variations for Tuberous Sclerosis-1 from CNVD:

6
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1974021617900000Copy numberTSC2Tuberous sclerosis
22475639130300000141213431Copy numberTSC1Tuberous sclerosis

Expression for genes affiliated with Tuberous Sclerosis-1

About this section
Search GEO for disease gene expression data for Tuberous Sclerosis-1.

Pathways for genes affiliated with Tuberous Sclerosis-1

About this section

Pathways related to Tuberous Sclerosis-1 according to GeneCards Suite gene sharing:

(show all 43)
idSuper pathwaysScoreTop Affiliating Genes
19.9MTOR, TSC1, TSC2
2
Show member pathways
9.6CDKN1B, MTOR, TSC2
39.5CDKN1B, MTOR, PTEN
49.4EIF4EBP1, MTOR, RAP1A
59.2CCL26, MTOR, RPS6KB1
69.1PTEN, RHEB, TSC1, TSC2
79.0CDKN1B, MTOR, RPS6KB1
88.9EIF4EBP1, MTOR, RPS6KB1
9
Show member pathways
8.9EIF4EBP1, MTOR, RPS6KB1
108.9MTOR, PTEN, RHEB, TSC1, TSC2
11
Show member pathways
8.9MTOR, PTEN, RHEB, TSC1, TSC2
12
Show member pathways
8.8CDKN1B, MTOR, NF1, PTEN, TSC1, TSC2
138.8CDKN1B, PTEN, RAP1A, RHEB
14
Show member pathways
8.7EIF4EBP1, MTOR, PTEN, RAP1A, RPS6KA1
15
Show member pathways
8.6EIF4EBP1, MTOR, RPS6KA1, RPS6KB1
16
Show member pathways
8.5EIF4EBP1, MTOR, RPS6KB1, TSC1, TSC2
178.5EIF4EBP1, MTOR, RPS6KB1, TSC1, TSC2
188.5CDKN1B, EIF4EBP1, MTOR, RPS6KB1
19
Show member pathways
8.5CDKN1B, EIF4EBP1, MTOR, RPS6KB1
20
Show member pathways
8.5CDKN1B, MTOR, RHEB, RPS6KA1, TSC1, TSC2
21
Show member pathways
8.5CDKN1B, MTOR, PTEN, RHEB, TSC1, TSC2
22
Show member pathways
8.4MTOR, PTEN, RAP1A, RPS6KA1, RPS6KB1
238.4CDKN1B, MTOR, RAP1A, RPS6KA1, RPS6KB1
24
Show member pathways
8.3EIF4EBP1, MTOR, PTEN, RPS6KB1, TSC2
258.3MTOR, NF1, PTEN, RAP1A, RHEB, TSC1
268.1EIF4EBP1, MTOR, RHEB, RPS6KB1, TSC2
27
Show member pathways
8.1EIF4EBP1, MTOR, RHEB, RPS6KB1, TSC2
288.1EIF4EBP1, MTOR, RAP1A, RPS6KA1, RPS6KB1, TSC2
298.0CDKN1B, MTOR, NF1, PTEN, RPS6KB1, TSC1
30
Show member pathways
7.9MTOR, PTEN, RAP1A, RHEB, RPS6KB1, TSC2
31
Show member pathways
7.9EIF4EBP1, MTOR, RHEB, RPS6KB1, TSC1, TSC2
32
Show member pathways
7.9EIF4EBP1, MTOR, RHEB, RPS6KB1, TSC1, TSC2
33
Show member pathways
7.9EIF4EBP1, MTOR, RHEB, RPS6KB1, TSC1, TSC2
34
Show member pathways
7.7EIF4EBP1, MTOR, PTEN, RHEB, RPS6KB1, TSC2
35
Show member pathways
7.5EIF4EBP1, MTOR, RHEB, RPS6KA1, RPS6KB1, TSC1
36
Show member pathways
7.5CCL26, CDKN1B, EIF4EBP1, MTOR, PTEN, RPS6KB1
377.2EIF4EBP1, MTOR, PTEN, RHEB, RPS6KA1, RPS6KB1
38
Show member pathways
7.2EIF4EBP1, MTOR, PTEN, RHEB, RPS6KA1, RPS6KB1
397.1CDKN1B, EIF4EBP1, MTOR, PTEN, RHEB, RPS6KB1
40
Show member pathways
7.1CDKN1B, EIF4EBP1, MTOR, PTEN, RHEB, RPS6KB1
41
Show member pathways
6.8CDKN1B, EIF4EBP1, MTOR, PTEN, RHEB, RPS6KA1
42
Show member pathways
6.6CCL26, CDKN1B, COL5A1, GFAP, MTOR, NF1
43
Show member pathways
6.0CDKN1B, EIF4EBP1, GFAP, MTOR, NF1, PTEN

GO Terms for genes affiliated with Tuberous Sclerosis-1

About this section

Cellular components related to Tuberous Sclerosis-1 according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1TSC1-TSC2 complexGO:003359610.9TSC1, TSC2
2neuron projectionGO:00430058.7DCX, PTEN, RAP1A, RPS6KB1, SYP
3membraneGO:00160207.7DBH, GFAP, MTOR, NF1, PKD1, RHEB
4cytoplasmGO:00057376.1CDKN1B, DBH, DCX, EIF4EBP1, GFAP, MTOR
5cytosolGO:00058295.6CDKN1B, DCX, EIF4EBP1, GFAP, MTOR, NF1

Biological processes related to Tuberous Sclerosis-1 according to GeneCards Suite gene sharing:

(show all 30)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of glial cell proliferationGO:006025210.6GFAP, MTOR
2negative regulation of macroautophagyGO:001624210.6MTOR, TSC1
3forebrain morphogenesisGO:004885310.5NF1, PTEN
4regulation of cell-matrix adhesionGO:000195210.5NF1, TSC1
5negative regulation of phosphatidylinositol 3-kinase signalingGO:001406710.4PTEN, TSC2
6negative regulation of cellular component movementGO:005127110.4CDKN1B, PKHD1
7positive regulation of endothelial cell proliferationGO:000193810.3CCL26, MTOR, NF1
8regulation of TOR signalingGO:003200610.2PKHD1, RHEB
9negative regulation of cell sizeGO:004579210.1MTOR, PTEN, TSC1
10positive regulation of oligodendrocyte differentiationGO:004871410.1MTOR, RHEB
11spinal cord developmentGO:002151010.0MTOR, NF1, PKD1
12regulation of synaptic transmission, GABAergicGO:003222810.0NF1, PTEN
13negative regulation of insulin receptor signaling pathwayGO:00466279.8RPS6KB1, TSC1, TSC2
14maternal behaviorGO:00427119.8DBH, PTEN
15response to insulinGO:00328689.8MTOR, RPS6KB1, TSC1
16heart developmentGO:00075079.7NF1, PKD1, PTEN, TSC2
17protein kinase B signalingGO:00434919.7PTEN, RPS6KB1, TSC2
18phosphatidylinositol-mediated signalingGO:00480159.6MTOR, PTEN, RPS6KB1
19cellular response to hypoxiaGO:00714569.6EIF4EBP1, MTOR, PTEN
20visual learningGO:00085429.6DBH, MTOR, NF1
21response to amino acidGO:00432009.6CDKN1B, MTOR, RPS6KB1
22response to nutrientGO:00075849.5MTOR, PTEN, RPS6KB1
23response to glucoseGO:00097499.4CDKN1B, PTEN, RPS6KB1
24TOR signalingGO:00319299.4EIF4EBP1, MTOR, RPS6KB1
25cellular response to organic cyclic compoundGO:00714079.3CDKN1B, RAP1A, RPS6KB1
26negative regulation of protein kinase B signalingGO:00518989.3PKHD1, PTEN, TSC2
27negative regulation of cell proliferationGO:00082859.1CDKN1B, NF1, PTEN, TSC1, TSC2
28G1/S transition of mitotic cell cycleGO:00000829.0CDKN1B, EIF4EBP1, RPS6KB1
29cell cycle arrestGO:00070509.0CDKN1B, MTOR, PKD1, RHEB, TSC1, TSC2
30negative regulation of apoptotic processGO:00430668.5CDKN1B, PKHD1, PTEN, RPS6KA1, RPS6KB1

Molecular functions related to Tuberous Sclerosis-1 according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1kinase activityGO:00163018.8MTOR, RPS6KA1, RPS6KB1
2protein kinase bindingGO:00199018.8DCX, MTOR, PKD1, PTEN, RHEB

Sources for Tuberous Sclerosis-1

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
26GTR
27HGMD
28HMDB
29ICD10
30ICD10 via Orphanet
31ICD9CM
32IUPHAR
33KEGG
36MedGen
38MeSH
39MESH via Orphanet
40MGI
43NCI
44NCIt
45NDF-RT
48NINDS
49Novoseek
51OMIM
52OMIM via Orphanet
56PubMed
57QIAGEN
62SNOMED-CT via Orphanet
66Tumor Gene Family of Databases
67UMLS
68UMLS via Orphanet